SAB Biotherapeutics, Inc.
corporate_fare Company Profile
SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for SABS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for SABS spans 10-Q, 8-K, SCHEDULE 13D/A, 424B5.
Recent high-impact activity:
- SAB Bio Q3 Loss Widens to $22.3M as R&D Spend Doubles; $205.3M Cash Covers One Year
- SAB Biotherapeutics Secures FDA Fast Track for SAB-142 in Stage 3 Type 1 Diabetes
- FDA Grants Fast Track to SAB-142 for New-Onset Type 1 Diabetes
- SAB Biotherapeutics Reports Q2 Loss, Secures $101.8M in Offerings & Warrants with 75% Share Dilution
- Breakthrough T1D Awards Grant to Support SAB-142 Clinical Study in Stage 3 Type 1 Diabetes
Financial Snapshot
Short Interest & Short Volume
8.28 days to coverFINRA reported short interest of 5,026,127 shares in SABS as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 8.3 days to cover at its recent average daily volume. On November 19, 2026, 25.4% of SABS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SABS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
Significant Dilution from Capital Raises · Extended Cash Runway
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →